Cargando…
A New Decellularization Protocol of Porcine Aortic Valves Using Tergitol to Characterize the Scaffold with the Biocompatibility Profile Using Human Bone Marrow Mesenchymal Stem Cells
The most common aortic valve diseases in adults are stenosis due to calcification and regurgitation. In pediatric patients, aortic pathologies are less common. When a native valve is surgically replaced by a prosthetic one, it is necessary to consider that the latter has a limited durability. In par...
Autores principales: | , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8949722/ https://www.ncbi.nlm.nih.gov/pubmed/35335556 http://dx.doi.org/10.3390/polym14061226 |
_version_ | 1784674972607709184 |
---|---|
author | Faggioli, Marika Moro, Arianna Butt, Salman Todesco, Martina Sandrin, Deborah Borile, Giulia Bagno, Andrea Fabozzo, Assunta Romanato, Filippo Marchesan, Massimo Imran, Saima Gerosa, Gino |
author_facet | Faggioli, Marika Moro, Arianna Butt, Salman Todesco, Martina Sandrin, Deborah Borile, Giulia Bagno, Andrea Fabozzo, Assunta Romanato, Filippo Marchesan, Massimo Imran, Saima Gerosa, Gino |
author_sort | Faggioli, Marika |
collection | PubMed |
description | The most common aortic valve diseases in adults are stenosis due to calcification and regurgitation. In pediatric patients, aortic pathologies are less common. When a native valve is surgically replaced by a prosthetic one, it is necessary to consider that the latter has a limited durability. In particular, current bioprosthetic valves have to be replaced after approximately 10 years; mechanical prostheses are more durable but require the administration of permanent anticoagulant therapy. With regard to pediatric patients, both mechanical and biological prosthetic valves have to be replaced due to their inability to follow patients’ growth. An alternative surgical substitute can be represented by the acellular porcine aortic valve that exhibits less immunogenic risk and a longer lifespan. In the present study, an efficient protocol for the removal of cells by using detergents, enzyme inhibitors, and hyper- and hypotonic shocks is reported. A new detergent (Tergitol) was applied to replace TX-100 with the aim to reduce toxicity and maximize ECM preservation. The structural integrity and efficient removal of cells and nuclear components were assessed by means of histology, immunofluorescence, and protein quantification; biomechanical properties were also checked by tensile tests. After decellularization, the acellular scaffold was sterilized with a standard protocol and repopulated with bone marrow mesenchymal stem cells to analyze its biocompatibility profile. |
format | Online Article Text |
id | pubmed-8949722 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-89497222022-03-26 A New Decellularization Protocol of Porcine Aortic Valves Using Tergitol to Characterize the Scaffold with the Biocompatibility Profile Using Human Bone Marrow Mesenchymal Stem Cells Faggioli, Marika Moro, Arianna Butt, Salman Todesco, Martina Sandrin, Deborah Borile, Giulia Bagno, Andrea Fabozzo, Assunta Romanato, Filippo Marchesan, Massimo Imran, Saima Gerosa, Gino Polymers (Basel) Article The most common aortic valve diseases in adults are stenosis due to calcification and regurgitation. In pediatric patients, aortic pathologies are less common. When a native valve is surgically replaced by a prosthetic one, it is necessary to consider that the latter has a limited durability. In particular, current bioprosthetic valves have to be replaced after approximately 10 years; mechanical prostheses are more durable but require the administration of permanent anticoagulant therapy. With regard to pediatric patients, both mechanical and biological prosthetic valves have to be replaced due to their inability to follow patients’ growth. An alternative surgical substitute can be represented by the acellular porcine aortic valve that exhibits less immunogenic risk and a longer lifespan. In the present study, an efficient protocol for the removal of cells by using detergents, enzyme inhibitors, and hyper- and hypotonic shocks is reported. A new detergent (Tergitol) was applied to replace TX-100 with the aim to reduce toxicity and maximize ECM preservation. The structural integrity and efficient removal of cells and nuclear components were assessed by means of histology, immunofluorescence, and protein quantification; biomechanical properties were also checked by tensile tests. After decellularization, the acellular scaffold was sterilized with a standard protocol and repopulated with bone marrow mesenchymal stem cells to analyze its biocompatibility profile. MDPI 2022-03-17 /pmc/articles/PMC8949722/ /pubmed/35335556 http://dx.doi.org/10.3390/polym14061226 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Faggioli, Marika Moro, Arianna Butt, Salman Todesco, Martina Sandrin, Deborah Borile, Giulia Bagno, Andrea Fabozzo, Assunta Romanato, Filippo Marchesan, Massimo Imran, Saima Gerosa, Gino A New Decellularization Protocol of Porcine Aortic Valves Using Tergitol to Characterize the Scaffold with the Biocompatibility Profile Using Human Bone Marrow Mesenchymal Stem Cells |
title | A New Decellularization Protocol of Porcine Aortic Valves Using Tergitol to Characterize the Scaffold with the Biocompatibility Profile Using Human Bone Marrow Mesenchymal Stem Cells |
title_full | A New Decellularization Protocol of Porcine Aortic Valves Using Tergitol to Characterize the Scaffold with the Biocompatibility Profile Using Human Bone Marrow Mesenchymal Stem Cells |
title_fullStr | A New Decellularization Protocol of Porcine Aortic Valves Using Tergitol to Characterize the Scaffold with the Biocompatibility Profile Using Human Bone Marrow Mesenchymal Stem Cells |
title_full_unstemmed | A New Decellularization Protocol of Porcine Aortic Valves Using Tergitol to Characterize the Scaffold with the Biocompatibility Profile Using Human Bone Marrow Mesenchymal Stem Cells |
title_short | A New Decellularization Protocol of Porcine Aortic Valves Using Tergitol to Characterize the Scaffold with the Biocompatibility Profile Using Human Bone Marrow Mesenchymal Stem Cells |
title_sort | new decellularization protocol of porcine aortic valves using tergitol to characterize the scaffold with the biocompatibility profile using human bone marrow mesenchymal stem cells |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8949722/ https://www.ncbi.nlm.nih.gov/pubmed/35335556 http://dx.doi.org/10.3390/polym14061226 |
work_keys_str_mv | AT faggiolimarika anewdecellularizationprotocolofporcineaorticvalvesusingtergitoltocharacterizethescaffoldwiththebiocompatibilityprofileusinghumanbonemarrowmesenchymalstemcells AT moroarianna anewdecellularizationprotocolofporcineaorticvalvesusingtergitoltocharacterizethescaffoldwiththebiocompatibilityprofileusinghumanbonemarrowmesenchymalstemcells AT buttsalman anewdecellularizationprotocolofporcineaorticvalvesusingtergitoltocharacterizethescaffoldwiththebiocompatibilityprofileusinghumanbonemarrowmesenchymalstemcells AT todescomartina anewdecellularizationprotocolofporcineaorticvalvesusingtergitoltocharacterizethescaffoldwiththebiocompatibilityprofileusinghumanbonemarrowmesenchymalstemcells AT sandrindeborah anewdecellularizationprotocolofporcineaorticvalvesusingtergitoltocharacterizethescaffoldwiththebiocompatibilityprofileusinghumanbonemarrowmesenchymalstemcells AT borilegiulia anewdecellularizationprotocolofporcineaorticvalvesusingtergitoltocharacterizethescaffoldwiththebiocompatibilityprofileusinghumanbonemarrowmesenchymalstemcells AT bagnoandrea anewdecellularizationprotocolofporcineaorticvalvesusingtergitoltocharacterizethescaffoldwiththebiocompatibilityprofileusinghumanbonemarrowmesenchymalstemcells AT fabozzoassunta anewdecellularizationprotocolofporcineaorticvalvesusingtergitoltocharacterizethescaffoldwiththebiocompatibilityprofileusinghumanbonemarrowmesenchymalstemcells AT romanatofilippo anewdecellularizationprotocolofporcineaorticvalvesusingtergitoltocharacterizethescaffoldwiththebiocompatibilityprofileusinghumanbonemarrowmesenchymalstemcells AT marchesanmassimo anewdecellularizationprotocolofporcineaorticvalvesusingtergitoltocharacterizethescaffoldwiththebiocompatibilityprofileusinghumanbonemarrowmesenchymalstemcells AT imransaima anewdecellularizationprotocolofporcineaorticvalvesusingtergitoltocharacterizethescaffoldwiththebiocompatibilityprofileusinghumanbonemarrowmesenchymalstemcells AT gerosagino anewdecellularizationprotocolofporcineaorticvalvesusingtergitoltocharacterizethescaffoldwiththebiocompatibilityprofileusinghumanbonemarrowmesenchymalstemcells AT faggiolimarika newdecellularizationprotocolofporcineaorticvalvesusingtergitoltocharacterizethescaffoldwiththebiocompatibilityprofileusinghumanbonemarrowmesenchymalstemcells AT moroarianna newdecellularizationprotocolofporcineaorticvalvesusingtergitoltocharacterizethescaffoldwiththebiocompatibilityprofileusinghumanbonemarrowmesenchymalstemcells AT buttsalman newdecellularizationprotocolofporcineaorticvalvesusingtergitoltocharacterizethescaffoldwiththebiocompatibilityprofileusinghumanbonemarrowmesenchymalstemcells AT todescomartina newdecellularizationprotocolofporcineaorticvalvesusingtergitoltocharacterizethescaffoldwiththebiocompatibilityprofileusinghumanbonemarrowmesenchymalstemcells AT sandrindeborah newdecellularizationprotocolofporcineaorticvalvesusingtergitoltocharacterizethescaffoldwiththebiocompatibilityprofileusinghumanbonemarrowmesenchymalstemcells AT borilegiulia newdecellularizationprotocolofporcineaorticvalvesusingtergitoltocharacterizethescaffoldwiththebiocompatibilityprofileusinghumanbonemarrowmesenchymalstemcells AT bagnoandrea newdecellularizationprotocolofporcineaorticvalvesusingtergitoltocharacterizethescaffoldwiththebiocompatibilityprofileusinghumanbonemarrowmesenchymalstemcells AT fabozzoassunta newdecellularizationprotocolofporcineaorticvalvesusingtergitoltocharacterizethescaffoldwiththebiocompatibilityprofileusinghumanbonemarrowmesenchymalstemcells AT romanatofilippo newdecellularizationprotocolofporcineaorticvalvesusingtergitoltocharacterizethescaffoldwiththebiocompatibilityprofileusinghumanbonemarrowmesenchymalstemcells AT marchesanmassimo newdecellularizationprotocolofporcineaorticvalvesusingtergitoltocharacterizethescaffoldwiththebiocompatibilityprofileusinghumanbonemarrowmesenchymalstemcells AT imransaima newdecellularizationprotocolofporcineaorticvalvesusingtergitoltocharacterizethescaffoldwiththebiocompatibilityprofileusinghumanbonemarrowmesenchymalstemcells AT gerosagino newdecellularizationprotocolofporcineaorticvalvesusingtergitoltocharacterizethescaffoldwiththebiocompatibilityprofileusinghumanbonemarrowmesenchymalstemcells |